Next up is Wendy St Peter Pharm D on the Challenges in Anemia Management. She starts with a Polling Question
Spoiler, according to table mate @nephrologyPharm, MSL for Amgen it is A. #NKFClinicals
Quick tour through Beserab CREATE, CHOIR, TREAT. Meta analysis #NKFClinicals
What effects the trials had on ESA use: Gold is Hgb, Grey is weekly EPO dose. TREAT caused overnight change in dosing.
LOUDER FOR THE PEOPLE IN THE BACK OF THE ROOM, “No significant association was found between improvements in Hgb levels with treatment and any of the 5-dimensions of quality of life.” #NKFClinicals
Now on to the Pivotal Trial of IV iron. N=2141 she reports is as no difference, but I thought after the correction there was a reduction in events? #oops #NKFClinicals
Just looked it up, I’m pretty sure I’m right here. #DoBetter #NKFClinicals
Okay, that distracted me and I missed the rest of her talk, but here is her conclusion slide #NKFClinicals
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.